| The Hemophilia Inhibitor Eradication Trial (NCT04303572) | Margaret Ragni | 2021-11-01 |
| SEVENFACT® for Bleeding Events in Hemophilia With Inhibitors (NCT04647227) | American Thrombosis and Hemostasis Network | 2021-06-28 |
| Study of Coagulation Factor VIIa Marzeptacog Alfa (Activated) in Subjects With Inherited Bleeding Disorders (NCT04548791) | Catalyst Biosciences | 2021-05-17 |
| Study of Coagulation Factor VIIa Marzeptacog Alfa (Activated) in Subjects With Hemophilia A or B (NCT04489537) | Catalyst Biosciences | 2021-05-04 |
| Study on the Dose-response Relationship of Pharmacodynamic Parameters in Patients With Hemophilia With Inhibitors (NCT04789954) | AryoGen Pharmed Co. | 2020-12-29 |
| Safety, Tolerability, and Efficacy Study of Valoctocogene Roxaparvovec in Hemophilia A With Active or Prior Inhibitors (NCT04684940) | BioMarin Pharmaceutical | 2020-12-10 |
| Study of Recombinant Human Coagulation Factor VIIa for Injection (FⅦa) in Patients With Hemophilia. (NCT04768699) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2020-12-01 |
| A Study to Evaluate the Safest Dose Range for FEIBA in Hemophilia A Patients With Inhibitors on Emicizumab (NCT04205175) | Children's Hospital Los Angeles | 2020-07-01 |
| An Exploration of the Impact of Emicizumab on the Lives of People With Haemophilia and Inhibitors and Their Families (NCT04723693) | Haemnet | 2020-02-28 |
| A Pharmacokinetic and Clotting Activity Study of FVIII-PEGLip (NCT04592692) | Ascension Healthcare Development Limited | 2019-12-23 |
| Study of Coagulation Faction VIIa Variant Marzeptacog Alfa (Activated) in Adult Subjects With Hemophilia (NCT04072237) | Catalyst Biosciences | 2019-09-24 |
| The Safety of Emicizumab SC Injection in Korean Hemophilia A Patients With/Without FVIII Inhibitors (NCT04805801) | JW Pharmaceutical | 2019-08-28 |
| rFVIIIFc (Elocta®) ITI Chart Review in Patients With Haemophilia A (NCT03951103) | Swedish Orphan Biovitrum | 2018-11-07 |
| ATHN 7: Hemophilia Natural History Study (NCT03619863) | American Thrombosis and Hemostasis Network | 2018-10-24 |
| ATHN 8: Previously Untreated Patients (PUPs) Matter Study (NCT03818529) | American Thrombosis and Hemostasis Network | 2018-10-03 |
| Study of Coagulation Factor VIIa Variant Marzeptacog Alfa (Activated) in Adult Subjects With Hemophilia A and B (NCT03407651) | Catalyst Biosciences | 2017-12-18 |
| INdividualized ITI Based on Fviii(ATE) Protection by VWF (NCT03204539) | University of California, Davis | 2017-06-01 |
| Prospective, Non-interventional Study to Evaluate Immunogenicity of AryoSeven (NCT03372993) | AryoGen Pharmed Co. | 2016-06-13 |
| Low-dose ITI Strategy for Children in Hemophilia A With High-titer Inhibitor and Poor ITI Risk in China (NCT03598725) | Beijing Children's Hospital | 2016-01-01 |
| Basic Study of Combination Therapy Based on APCC-induced FVllI Activation in Hemophilia A Patients With Inhibitors (NCT02554526) | Nara Medical University | 2015-09-01 |
| Hemophilia Inhibitor Genetics Study (HIGS) (NCT00166387) | Skane University Hospital | 2003-04-01 |